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BACKGROUND: There is limited evidence that imaging biomarkers can predict subsequent response to therapy. Such prognostic and/or
predictive biomarkers would facilitate development of personalised medicine. We hypothesised that pre-treatment measurement of
the heterogeneity of tumour vascular enhancement could predict clinical outcome following combination anti-angiogenic and
cytotoxic chemotherapy in colorectal cancer (CRC) liver metastases.
METHODS: Ten patients with 26 CRC liver metastases had two dynamic contrast-enhanced MRI (DCE-MRI) examinations before
starting first-line bevacizumab and FOLFOX-6. Pre-treatment biomarkers of tumour microvasculature were computed and a
regression analysis was performed against the post-treatment change in tumour volume after five cycles of therapy. The ability of the
resulting linear model to predict tumour shrinkage was evaluated using leave-one-out validation. Robustness to inter-visit variation
was investigated using data from a second baseline scan.
RESULTS: In all, 86% of the variance in post-treatment tumour shrinkage was explained by the median extravascular extracellular
volume (ve), tumour enhancing fraction (EF), and microvascular uniformity (assessed with the fractal measure box dimension, d0)
(R
2¼0.86, Po0.00005). Other variables, including baseline volume were not statistically significant. Median prediction error was 12%.
Equivalent results were obtained from the second scan.
CONCLUSION: Traditional image analyses may over-simplify tumour biology. Measuring microvascular heterogeneity may yield
important prognostic and/or predictive biomarkers.
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There is considerable interest in developing pre-treatment
biomarkers of microvascular structure and function that predict
subsequent therapeutic response (O’Connor et al, 2008). Develop-
ment and validation of such biomarkers will be essential if
personalised therapy is to become a reality (Meyer et al, 2009).
Tumour size is an important factor in staging some solid
tumours, selecting treatment options, and in predicting clinical
outcome (Edge et al, 2010). However, for some solid tumours, size
has little relevance to tumour stage and the link between pre-
treatment tumour size and outcome is complex, with no clear
relationship between the two (Grigsby et al, 1999; Foulkes et al,
2008; Klatte et al, 2008).
Tumour function may also predict outcome, particularly in
the setting of novel adjuvant therapies. Techniques such as
18F-fluorodeoxyglucose positron emission tomography (
18F-FDG-
PET) and dynamic contrast-enhanced MRI (DCE-MRI) offer the
opportunity to study tumour pathophysiology (O’Connor et al,
2008). For example, simple summary values such as high baseline
18FDG-PET standardised uptake value (Dimitrakopoulou-Strauss
et al, 2004; de Geus-Oei et al, 2006) and high baseline DCE-MRI
volume transfer constant (K
trans) (George et al, 2001) before
therapy have shown statistically significant relationships with
beneficial clinical outcome following various cytotoxic treatments
in patients with colorectal cancer (CRC). However, current
evidence that these biomarkers accurately predict clinical outcome
is limited (O’Connor et al, 2007a; Kinahan et al, 2009).
This relative lack of success has fuelled interest in alternative
biomarkers of microvascular structure and function that may
better serve as predictive and/or prognostic biomarkers. There is
emerging evidence that tumours are biologically complex struc-
tures exhibiting marked spatial variation in angiogenesis (Kumar
et al, 1998; Eberhard et al, 2000), hypoxia (Picchio et al, 2008), cell
death (Gonzalez-Garcia et al, 2002), and glucose metabolism
(Schroeder et al, 2005). The presence and degree of heterogeneity
may be an important determinant of cancer metastatic potential
(Fidler, 1987) and response to therapy (Casanovas et al, 2005).
Despite this, measurement of tumour heterogeneity is largely
ignored in radiological practice.
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sPrevious imaging studies have provided evidence of a relation-
ship between the spatial heterogeneity of image biomarkers of the
tumour vasculature (such as T1 signal change, K
trans, blood
volume, and Hounsfield units) and therapeutic response (Jackson
et al, 2007). Several differing approaches have been studied,
including histogram analysis (Chang et al, 2004) and measuring
the proportion of the tumour that enhances (O’Connor et al,
2007b). Both of these approaches summarise the distribution of
tumour functional properties but ignore the spatial location of
individual tumour voxels (and their vascular, metabolic, or other
features) and the relationship of one voxel to another within a
lesion. Alternative approaches such as texture (El Naqa et al, 2009)
or fractal analysis (Dzik-Jurasz et al, 2004; Rose et al, 2007; Goh
et al, 2009; Alic et al, 2011) quantify the overall spatial complexity
of a tissue and retain information regarding the spatial arrange-
ment of voxels within a tumour. In this study, we tested the
hypothesis that tumour measurements of microvascular function
and heterogeneity computed from pre-treatment DCE-MRI data
would predict tumour shrinkage following combination therapy
with anti-angiogenic and cytotoxic chemotherapy.
MATERIALS AND METHODS
Study design
Retrospective analysis was performed on DCE-MRI data collected
between July 2006 and October 2007 in 10 patients with CRC liver
metastases. Patients were originally recruited for an investigator
led study that examined the temporal action of bevacizumab
during a single cycle of therapy (O’Connor et al, 2009). Ethical
approval was granted by the local Research Ethics Committee and
informed consent was obtained. All patients received single agent
10mgkg
–1 bevacizumab (cycle 1) followed every 2 weeks by
10mgkg
–1bevacizumab plus FOLFOX-6 (oxaliplatin/5FU/leucovorin)
for 2 months (cycles 2–5) as first-line treatment.
Patient recruitment
Patients with histologically proven primary epithelial CRC, aged
X18 years, with an Eastern Cooperative Oncology Group score
between 0 and 2, and life expectancy of at least 3 months were
eligible. Enrolment of patients who required first-line treatment
for metastatic disease was consecutive. Inclusion criteria were
presence of a measurable lesion X2cm on previous imaging;
adequate liver, renal, and haematologic function; normal coagula-
tion (prothrombin time and activated partial thromboplastin
time); normal ECG.
Exclusion criteria were previous treatment with vascular
endothelial growth factor (VEGF) inhibitors or cytotoxic che-
motherapy; contraindications to VEGF inhibitors; exposure to any
other investigational drug (within the last 4 weeks) or concurrent
therapy likely to influence the vasculature on imaging; pregnant or
breast-feeding women; previous clinically significant haemorrhage,
thrombosis, or cardiovascular disease within the last 6 months;
proteinuria; contraindication to MRI.
MRI data acquisition
Patients were examined on a 1.5-T Philips Intera system (Philips
Medical Systems, Best, The Netherlands). Each patient was
scanned twice before treatment, to allow measurement reliability
to be assessed. In one patient (with three tumours), data were only
available from one pre-treatment scan. The field of view (FOV) was
centred on the liver. In each examination, T1-weighted fast field
echo images (TR¼10ms, TE¼4.6ms, a¼151) and T2-weighted
single shot turbo spin echo images (TR¼606.5ms, TE¼80ms,
a¼901) were acquired. Both sequences employed FOV
375 375mm
2, matrix 256 256 with a 4-mm slice thickness.
For the DCE-MRI series, 75 3D axial volumes were acquired
consecutively (TR¼4.0ms, TE¼0.82ms, a¼201, one signal
average, FOV of 375 375mm
2, matrix 128 128; in-plane voxel
size 2.93 2.93mm
2) following calculation of baseline T1 using the
variable flip angle method (Fram et al, 1987) (a¼21/101/201; four
signal averages; identical TR, TE, imaging matrix, and slice
thickness). Temporal resolution was 4.97s. On the sixth dynamic
time point, 0.1mmolkg
–1of Gadodiamide (Omniscan GE Medical
Systems, Amersham, UK) was administered intravenously through
a Spectris MR power injector (Medrad Inc., Indianola, PA, USA) at
3mls
–1, followed by a saline flush. Slice thickness was 4mm for
small target lesions or 8mm for larger lesions, giving superior–
inferior coverage of either 100 or 200mm. Images were acquired
during gentle free breathing.
Calculation of tumour volume and summary DCE-MRI
statistics
Quality control was applied to reduce error in all image
parameters. The impact of motion was assessed and tumours for
which parameter estimates would be unreliable were rejected. The
level of bulk motion was assessed for each tumour by first
extracting an averaged time series plot for each tumour region of
interest (ROI) on each slice in the imaging volume and then by
visual assessment of the dynamic time series images. In- and
through-plane motion was investigated and a categorical score was
assigned for each tumour based on the evaluations of bulk motion
(slight motion¼1, moderate motion¼2, significant motion¼3,
and severe motion¼4). Tumours with a motion assessment score
of 3 or 4 were excluded.
Three-dimensional ROIs were defined on coregistered high-
resolution T1- and T2-weighted sequences. In some patients,
multiple lesions were defined. To quantify microvascular char-
acteristics, the extended Tofts version of the Kety model (Tofts,
1997) was fitted to the DCE-MRI time series at each enhancing
tumour voxel (see below) using in-house software, as given by
CtðtÞ¼vpCpðtÞþKtrans
Z t
0
Cpðt0Þexp
 Ktrans t   t0 ðÞ
ve
  
dt0 ð1Þ
where Ct(t) is the concentration of contrast agent at time t in each
voxel and Cp(t) is the concentration of contrast agent in the arterial
blood plasma (i.e., the arterial input function, which was
determined using a previously published population AIF technique
(Parker et al, 2006)). The extended Tofts model is only valid in
tumour regions in which there is a measurable signal change due
to the presence of contrast agent. To identify those voxels, a
previously published method was used in which pre- and
post-injection concentration values are statistically compared
(O’Connor et al, 2009).
Voxel-wise analysis was performed allowing estimates of the
median bulk transfer coefficient (K
trans; units min
 1; Figure 1A),
mean fractional plasma volume (vp; unitless) and median
fractional volume of the extravascular extracellular space (ve;
unitless).
Calculation of heterogeneity statistics
The following three types of heterogeneity statistic were derived:
1. Enhancing fraction (EF, defined as the ratio of the number of
enhancing voxels to total tumour voxels; EF¼NE/NT) was
calculated to characterise the overall level of tumour perfusion
(Figure 1B). Voxels with pre-contrast and post-contrast agent
time series that had significantly different distributions (where
Po0.05 on Mann–Whitney Wilcoxon rank-sum test) were
classified as enhancing (O’Connor et al, 2007b).
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trans, ve, and vp
measurements were calculated for the enhancing portion of
each tumour.
3. Fractal summaries (measures of microvascular structure and
function that consider spatial information) were derived from
the DCE-MRI data. The calculation of one of these fractal
measures, box dimension (d0), is illustrated (Figures 1C and D),
where a binary image corresponding to enhancing tumour
voxels is iteratively subsampled by a factor of two to define
binary images at a range of scales; at each scale, the enhancing
voxels are counted and d0 is calculated as the rate of change in
the number of enhancing voxels with respect to scale (with both
quantities considered on logarithmic scales). In addition,
fractal measures based on the information dimension (d1)
and correlation dimension (d2) were calculated. These latter
metrics retain magnitude values of K
trans, ve, and vp and are
described in detail elsewhere (Rose et al, 2009).
Evaluation of tumour shrinkage
X-ray computed tomography (CT) examination of the abdomen
and pelvis was performed at baseline within 72h of the baseline
MRI and at the end of cycle 5 (EC5) to evaluate clinical response.
Patients were imaged on a LightSpeed Plus CT scanner (GE
Medical Systems), with typical clinical helical acquisition variables
(tube voltage 120kV, tube current 40mA). Images were acquired
following intravenous injection of 200ml Omnipaque-140 (GE
Medical Systems) and reformatted to produce contiguous 5mm
slices with no overlap. Tumour volumes were measured (in mm
3)
and the remaining tumour volume (%) from baseline to EC5 was
calculated by comparison with the pre-treatment tumour volume.
Statistical analysis
Percentage of remaining tumour volume at EC5 was modelled as a
linear function of the pre-treatment summary statistics described
above. Before modelling, variables were transformed as appro-
priate to improve linearity (e.g., by taking logarithms). In a
preliminary analysis, a mixed-effects model was used to explore
potential within-patient clustering since some patients had more
than one tumour. However, no statistically significant evidence for
such effects was found. Subsequently, tumours were treated
independently.
Stepwise errors-in-variables regression was used to model the
percentage of remaining tumour volume based on the pre-
treatment volume, summary DCE-MRI statistics, and heterogene-
ity statistics using data from the first pre-treatment scan. The
regression was repeated using the data from the second scan to
investigate robustness to inter-visit variation. In the above
analyses, the missing data for one patient’s first pre-treatment
scan (three tumours) were dealt with using list-wise deletion or
imputation (from the second scan) as appropriate, with the aim of
maximising the amount of data available, while minimising bias.
The ability of the linear model to predict tumour response was
evaluated using two leave-one-out analyses. In the first analysis,
each tumour was left out in turn; the coefficients on each variable
were computed—by applying errors-in-variables regression to the
left-in tumours’ data—and used to predict the response of the left-
out tumour. In the second analysis, the data for each patient was
left out in turn (allowing us to further investigate potential intra-
patient clustering effects); the coefficients on each variable were
computed—by applying errors-in-variables regression to the left-
in patients’ data—and used to predict the responses for the
tumours in the left-out patients.
Prediction error was quantified using the absolute difference
between the actual and predicted percentage of remaining tumour
volume. A cumulative distribution function (CDF) of prediction
error was plotted for each leave-one-out analysis; a CDF permits
estimation of the proportion of predictions that would be expected
to be less than or equal to a given prediction error. Bland–Altman
plots were formed to assess the agreement between actual and
predicted percentage of the remaining tumour volume.
Statistical modelling was performed using Stata/IC version 10.1
(Stata Corporation, College Station, TX, USA) and leave-one-out
analysis was performed using Mathematica version 7.0.1 (Wolfram
Research, Champaign, IL, USA).
RESULTS
The mean patient age was 68.3 years (range 61–78 years; eight
males; two females). All patients completed therapy to EC5. Two
patients achieved partial responses; seven had stable disease; one
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Figure 1 Derivation of a thresholded parameter map to enable calculation of enhancing fraction (EF) and box dimension (d0). (A) K
trans map across a
single slice within a CRC liver metastasis shows marked spatial heterogeneity. (B) A criterion is applied to the contrast agent concentration time series to
identify enhancing voxels (NE) and the resultant map is shown. EF is calculated as the ratio of NE to the number of tumour voxels (NT). (C) A box
surrounding the object defined by the enhancing voxels is successively divided, defining a range of scales (s) at which the number of boxes containing a part
of the object is counted (n). (D) d0 is the slope of the line of best fit through the points (log n, log 1/s) and quantifies the space filling properties of the
parameter map.
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shad disease progression by RECIST 1.0 criteria. In all, 26 tumours
were identified in the 10 patients (mean 2.6, median 2.5).
The final errors-in-variables regression analysis modelled
tumour response in terms of the following pre-treatment
biomarkers: median ve, EF, and d0 (details in Table 1). This model
explained 86% of the variance in tumour response (95%
confidence interval 77–94%). When the regression was repeated
for the second pre-treatment scan data, no significant differences
between the coefficients estimated for each variable, or between
the R
2 values, were found; however, median ve was not quite
significant within this second model (P¼0.07). This suggests that
the identified variables and the underlying model are robust to
typical inter-visit variation. Scatter plots showing the relationships
between the retained variables and percentage remaining tumour
volume are provided in Figure 2.
The results of the two leave-one-out analyses suggest that
tumour response can be predicted with an error of no more than
12% in 50% of cases, and with an error of no more than 31% in
80% of cases (Figure 3). No difference was observed between the
leave-one-out analysis that treated tumours independently and
that grouped tumours at the patient level, indicating no evidence
for intra-patient clustering.
The Bland–Altman plots for the leave-one-tumour- and leave-
one-patient-out predictions were very similar, with the differences
(vertical axes) having almost identical mean ( 0.04%) and
standard deviation (30%) (Figure 4). In one tumour, the remaining
tumour volume was predicted particularly poorly (the model
dramatically underestimates the actual change). There was no
statistically significant relationship between the means and
differences.
DISCUSSION
In this study, we have investigated the relative value of pre-
treatment biomarkers of the microvasculature in explaining the
percentage of remaining tumour volume resulting from combined
bevacizumab and FOLFOX-6 therapy. We hypothesised that
tumour size change could be explained by baseline image data,
but that simple measures of size or function (used individually)
may lack predictive power.
In this data set, 86% of the variance in the outcome measure
(percentage remaining tumour volume EC5) was explained by
combining various pre-treatment imaging biomarkers. Impor-
tantly, robustness to inter-visit variation was validated by a second
data set derived from the same tumours. Of note, pre-treatment
tumour volume was not found to be a statistically significant
determinant of subsequent change in tumour volume following
treatment. However, three variables (ve, EF, and d0) were
statistically significant within the model and provide complemen-
tary types of information about the tumour environment. These
results are congruent with other studies, which report that multi-
parametric image analyses may be better at predicting clinical
outcome (Dimitrakopoulou-Strauss et al, 2004, 2010), compared
with more traditional analyses based around a single parameter.
Median ve is an estimate of the extracellular extravascular space
affected by factors including cell size, number, and packing
density. It also represents a direct estimate of the distribution
space to which a contrast agent or drug can be delivered. Different
studies have reported variably either decrease or increase in
median ve in small numbers of patients following anti-vascular
therapy. No study has reported how this parameter may relate to a
measure of clinical outcome. In this study, high median ve was
Table 1 Result of the errors-in-variables regression shows: the model’s
F statistic, P, and R
2 values
F3,22 25.86
P p0.00005
R
2 0.86
Variable Coefficient TP 4|t| 95% CI on coefficient
ve  147.08  3.37 0.003  237.49  56.67
EF  2.35  8.46 p0.0005  2.93  1.78
d0 156.10 4.04 0.001 75.91 236.30
Constant  47.19  0.68 0.506  191.83 97.45
Abbreviations: d0¼fractal measure box dimension; EF¼enhancing fraction;
ve¼median extravascular extracellular space volume. The variables listed were
significant in the final model (corresponding coefficients, t statistics, P values, and 95%
confidence intervals (CIs) are provided). The constant term in the linear model is also
included.
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Figure 2 Scatter plots showing the relationship between (A) median ve,
(B) EF, and (C) d0 and remaining tumour volume (%).
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potential for greater extravasations of chemotherapy and bevaci-
zumab into the extracellular extravascular space.
Two measures of tumour vascular heterogeneity – EF and d0 –
were also statistically significant in this study. EF is the ratio of
enhancing tumour voxels to overall tumour voxels. As such, it is a
crude indicator of heterogeneity by quantifying the proportion of a
tumour that has demonstrable delivery and retention of contrast
agent. For example, a tumour with cystic or necrotic components
has a lower EF than a predominantly solid lesion. The parameter is
repeatable with a low coefficient of variation (O’Connor et al,2 0 0 9 )
and is sensitive to the therapeutic effect of anti-angiogenic and anti-
vascular compounds (Galbraith et al,2 0 0 3 ;R o b i n s o net al, 2003;
O’Connor et al,2 0 0 9 ) .I nt h i ss t u d y ,h i g hEF was associated with
better tumour response. This is consistent with identifying tumours
with a high proportion of well-perfused tissue that receive
substantial penetration of systemically administered agents.
Previous studies have reported that high baseline EF predicted
poor response to cytotoxic chemotherapy in epithelial ovarian
cancer (O’Connor et al, 2007b) and radiotherapy in cervical cancer
(Donaldson et al, 2010), attributed to a high EF representing a
greater amount of neo-angiogenic tumour tissue. This apparent
discrepancy may reflect the fact that EF is a non-specific marker
that is influenced by several physiological correlates including
flow, permeability, vascular volume, extravascular leakage space,
and interstitial pressure. EF may therefore, be best interpreted
relative to normal tissue values rather than absolute values that
may indicate prognosis. The type of treatment employed and
method of calculating enhancement also vary between studies and
alter the relative meaning of a high or low EF.
Enhancing fraction and ve disregard spatial information; two
parameter maps with identical EF or ve values can have completely
different spatial distributions of either parameter (Rose et al,
2009). For this reason, there has been interest in developing
metrics such as box dimension that quantify the spatial hetero-
geneity present within parametric imaging maps of tumours (Goh
et al, 2009). In this study, low box dimension (d0) was associated
with better tumour response. This parameter can be low if there
are few enhancing voxels or if enhancing voxels are non-uniformly
distributed. The proportion of enhancing voxels is already
captured in EF but d0 is also significant, implying that the spatial
arrangement of enhancing tissue within a tumour (and therefore
the uniformity of drug delivery) is important. As used here,
d0 reflects not only microvascular uniformity but also depends on
tumour shape. Our data are comparable to a study of rectal
carcinoma treated by cytotoxic chemotherapy, where a similar
parameter calculated from pre-treatment thresholded single slice
parameter maps for area under the DR2* curve (where R2*¼1/T2*)
predicted tumour regression after 8 weeks of therapy (Dzik-Jurasz
et al, 2004) and a study of limb sarcomas where fractal dimension
distinguished responders from non-responders (Alic et al, 2011).
The CDFs presented in Figure 3 show that in general, percentage
remaining tumour volume can be predicted with relatively little
error in this particular clinical scenario. This application may be
extremely useful for the selection of patients likely to benefit from
expensive novel therapies, as it may be possible to identify patients
whose tumours that are more or less likely to respond to therapy.
The little difference between the CDFs for the leave-one-tumour-
and leave-one-patient-out analyses, suggest that the ability of the
variables identified to predict tumour response cannot easily be
explained by the influence of patients with multiple tumours. The
resulting model explains a large proportion (86%) of the total
variance in tumour response and allows tumour response to be
predicted with excellent accuracy in the majority of cases. However,
while the variables were highly significant within the model, the
confidence intervals on their coefficients are wide; a larger sample
would be required to estimate these coefficients with more
confidence. The model was also robust to inter-visit variation,
since the same variables were significant (with the exception of
median ve), and there were no significant differences between the
coefficient or R
2 values – providing internal validation.
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Figure 4 Bland–Altman plots for (A) leave-one-tumour-out and (B)
leave-one-patient-out predictions, showing the mean difference between
the actual and predicted changes in volume, and that mean ±2 s.d. of the
differences.
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all cases.
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Second, the imaging parameters used require significant post-
processing effort to obtain and do not have accepted standardisa-
tion. Third, while the biomarkers identified appear to predict
shrinkage, they require testing against survival in a larger study.
Fourth, respiratory or other patient motion can complicate any
image analysis, particularly those performed on a per voxel
basis (Orton et al, 2009). Image registration can be used to salvage
motion-corrupted data, but requires additional post-processing
work, limiting its applicability in clinical settings (Buonaccorsi
et al, 2006, 2007). Our results demonstrate that tumour shrinkage
can be predicted even in the presence of typical patient
motion (however, note that we did reject data that were corrupted
by very significant motion). Future work should determine
if image registration offers any advantage in the context of
predicting tumour shrinkage or survival. Finally, in addition to
seeking to improve prediction accuracy, future work should also
investigate the use of imaging (or other) information to identify
tumours for which the kind of model proposed here would
perform poorly.
In conclusion, these data provide preliminary evidence that a
combination of pre-treatment measures derived from DCE-MRI
parameter maps may predict tumour shrinkage in response to
combined bevacizumab and cytotoxic chemotherapy in CRC liver
metastases, with relatively low error. Although the applicability of
these results to other tumours types and metastatic disease in other
organs cannot be inferred from the data presented, this type of
approach may have value in determining personalised tumour
therapy regimes and patient selection. These results encourage the
further evaluation of image heterogeneity in cancer studies using
MRI, PET, and other techniques, to explore whether similar
findings are seen in alternative combinations of patient group,
therapy, and imaging technique.
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